{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:53:00Z","timestamp":1791010380825,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02298-7","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:16:35Z","timestamp":1791008195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reconstruction robustness of liver-referenced adaptive thresholding for 68Ga-PSMA-11 PET\/CT volumetry: a comparative analysis of systematic bias and individual-patient variability"],"prefix":"10.1007","author":[{"given":"Ellen","family":"Sch\u00f6tz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2434-4883","authenticated-orcid":false,"given":"Dominic","family":"Ufton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Weindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin S.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"4","key":"2298_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48(4):1200\u201310. https:\/\/doi.org\/10.1007\/s00259-020-05040-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2298_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"issue":"5","key":"2298_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"issue":"2","key":"2298_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00259-021-05473-2","volume":"49","author":"N Capobianco","year":"2022","unstructured":"Capobianco N, Sibille L, Chantadisai M, Gafita A, Langbein T, Platsch G, et al. Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET\/CT using dual-tracer learning. Eur J Nucl Med Mol Imaging. 2022;49(2):517\u201326. https:\/\/doi.org\/10.1007\/s00259-021-05473-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2298_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kr\u00f6nke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68 Ga-PSMA11 PET\/CT. J Nucl Med. 2019;60(9):1277\u201383. https:\/\/doi.org\/10.2967\/jnumed.118.224055.","journal-title":"J Nucl Med"},{"issue":"5","key":"2298_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","volume":"46","author":"B Grubm\u00fcller","year":"2019","unstructured":"Grubm\u00fcller B, Senn D, Kramer G, Baltzer P, D\u2019Andrea D, Grubm\u00fcller KH, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1063\u201372. https:\/\/doi.org\/10.1007\/s00259-018-4236-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2298_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00259-015-3165-8","volume":"43","author":"G Kuhnert","year":"2016","unstructured":"Kuhnert G, Boellaard R, Sterzer S, Kahraman D, Scheffler M, Wolf J, et al. Impact of PET\/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Eur J Nucl Med Mol Imaging. 2016;43(2):249\u201358. https:\/\/doi.org\/10.1007\/s00259-015-3165-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2298_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/RLU.0b013e318279b9df","volume":"38","author":"E Prieto","year":"2013","unstructured":"Prieto E, Dom\u00ednguez-Prado I, Garc\u00eda-Velloso MJ, Pe\u00f1uelas I, Richter J\u00c1, Mart\u00ed-Climent JM. Impact of Time-of-Flight and Point-Spread-Function in SUV Quantification for Oncological PET. Clin Nucl Med. 2013;38(2):103. https:\/\/doi.org\/10.1097\/RLU.0b013e318279b9df.","journal-title":"Clin Nucl Med"},{"issue":"Supplement 2","key":"2298_CR9","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.2967\/jnumed.110","volume":"52","author":"R Boellaard","year":"2011","unstructured":"Boellaard R. Need for Standardization of 18F-FDG PET\/CT for Treatment Response Assessments. J Nucl Med. 2011;52(Supplement 2):S93\u2013100. https:\/\/doi.org\/10.2967\/jnumed.110. .085662 PubMed PMID: 22144561.","journal-title":"J Nucl Med"},{"key":"2298_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12880-021-00699-w","volume":"21","author":"K Huang","year":"2021","unstructured":"Huang K, Feng Y, Liang W, Li L. Impact of time of flight and point spread function on quantitative parameters of lung lesions in 18F-FDG PET\/CT. BMC Med Imaging. 2021;21:169. https:\/\/doi.org\/10.1186\/s12880-021-00699-w . PubMed PMID: 34773998; PubMed Central PMCID: PMC8590319.","journal-title":"BMC Med Imaging"},{"key":"2298_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-016-0169-9","volume":"4","author":"OL Munk","year":"2017","unstructured":"Munk OL, Tolbod LP, Hansen SB, Bogsrud TV. Point-spread function reconstructed PET images of sub-centimeter lesions are not quantitative. EJNMMI Phys. 2017;4:5. https:\/\/doi.org\/10.1186\/s40658-016-0169-9 . PubMed PMID: 28091957; PubMed Central PMCID: PMC5236043.","journal-title":"EJNMMI Phys"},{"issue":"7","key":"2298_CR12","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1016\/j.acra.2023.12.016","volume":"31","author":"H Knaup","year":"2024","unstructured":"Knaup H, Weindler J, Van Heek L, Voltin CA, Fuchs M, Borchmann P, et al. PET\/CT Reconstruction and Its Impact on [Measures of] Metabolic Tumor Volume. Acad Radiol. 2024;31(7):3020\u20135. https:\/\/doi.org\/10.1016\/j.acra.2023.12.016.","journal-title":"Acad Radiol"},{"issue":"10","key":"2298_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/MNM.0000000000002021","volume":"46","author":"D Ufton","year":"2025","unstructured":"Ufton D, Heilinger J, Roth KS, Schmidt M, Drzezga A, Kobe C. A comparison between two image reconstructions on the measures of prostate-specific membrane antigen\u2013positive tumor volume in 18F-PSMA-JK-7-PET\/computed tomography. Nucl Med Commun. 2025;46(10):967. https:\/\/doi.org\/10.1097\/MNM.0000000000002021.","journal-title":"Nucl Med Commun"},{"issue":"16","key":"2298_CR14","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"issue":"11","key":"2298_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12149-024-01957-x","volume":"38","author":"A Ar\u00e7ay \u00d6zt\u00fcrk","year":"2024","unstructured":"Ar\u00e7ay \u00d6zt\u00fcrk A, Erk\u0131l\u0131\u00e7 M, Bural GG, Ayd\u0131n F, Boz A. Physiological biodistribution on Ga68-PSMA PET\/CT and the factors effecting biodistribution. Ann Nucl Med. 2024;38(11):894\u2013903. https:\/\/doi.org\/10.1007\/s12149-024-01957-x . PubMed PMID: 38980577; PubMed Central PMCID: PMC11489224.","journal-title":"Ann Nucl Med"},{"key":"2298_CR16","doi-asserted-by":"publisher","first-page":"663631","DOI":"10.3389\/fonc.2021.663631","volume":"11","author":"LM Mittlmeier","year":"2021","unstructured":"Mittlmeier LM, Brendel M, Beyer L, Albert NL, Todica A, Zacherl MJ, et al. Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET\/CT Imaging in Prostate Cancer Patients. Front Oncol. 2021;11:663631. https:\/\/doi.org\/10.3389\/fonc.2021.663631 . PubMed PMID: 34094956; PubMed Central PMCID: PMC8176856.","journal-title":"Front Oncol"},{"issue":"4","key":"2298_CR17","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr., Wang CY, et al. Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues. World J Surg. 2006;30(4):1658. https:\/\/doi.org\/10.1007\/s00268-005-0544-5.","journal-title":"World J Surg"},{"issue":"4","key":"2298_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00259-020-05059-4","volume":"48","author":"C Draulans","year":"2021","unstructured":"Draulans C, De Roover R, van der Heide UA, Kerkmeijer L, Smeenk RJ, Pos F, et al. Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(4):1211\u20138. https:\/\/doi.org\/10.1007\/s00259-020-05059-4 . PubMed PMID: 33025093.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2298_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, H\u00fcsing J, Claassen K, M\u00f6ller L, Kaj\u00fcter H, Oesterling F, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25(9):1188\u2013201. 2045(24)00326-7 PubMed PMID: 39089299.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2298_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S1470-2045(26)00016-1","volume":"27","author":"MJ Karpinski","year":"2026","unstructured":"Karpinski MJ, Civan C, Rauscher I, G\u00fcven O, Eiber M, Hober\u00fcck S, et al. New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. Lancet Oncol. 2026;27(4):480\u201390. 2045(26)00016-1 PubMed PMID: 41819113.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2298_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2967\/jnumed.122.264489","volume":"64","author":"F Kind","year":"2023","unstructured":"Kind F, Eder AC, Jilg CA, Hartrampf PE, Meyer PT, Ruf J, et al. Prognostic Value of Tumor Volume Assessment on PSMA PET After 177 Lu-PSMA Radioligand Therapy Evaluated by PSMA PET\/CT Consensus Statement and RECIP 1.0. J Nucl Med. 2023;64(4):605\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264489.","journal-title":"J Nucl Med"},{"issue":"1","key":"2298_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13550-024-01190-7","volume":"15","author":"J Heilinger","year":"2025","unstructured":"Heilinger J, Roth KS, Weis H, Fink A, Weindler J, Dietlein F, et al. Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy. EJNMMI Res. 2025;15(1):4. https:\/\/doi.org\/10.1186\/s13550-024-01190-7 . PubMed PMID: 39792324; PubMed Central PMCID: PMC11723865.","journal-title":"EJNMMI Res"},{"issue":"1","key":"2298_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13550-022-00916-9","volume":"12","author":"MC Ferr\u00e1ndez","year":"2022","unstructured":"Ferr\u00e1ndez MC, Eertink JJ, Golla SSV, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, et al. Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods. EJNMMI Res. 2022;12(1):44. https:\/\/doi.org\/10.1186\/s13550-022-00916-9.","journal-title":"EJNMMI Res"},{"issue":"1","key":"2298_CR24","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023;308(1):e222148. https:\/\/doi.org\/10.1148\/radiol.222148.","journal-title":"Radiology"},{"issue":"1","key":"2298_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-019-0540-7","volume":"9","author":"M Hohberg","year":"2019","unstructured":"Hohberg M, Kobe C, Krapf P, T\u00e4ger P, Hammes J, Dietlein F, et al. Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET\/CT imaging of prostate cancer. EJNMMI Res. 2019;9(1):66. https:\/\/doi.org\/10.1186\/s13550-019-0540-7.","journal-title":"EJNMMI Res"},{"issue":"1","key":"2298_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T, Spielhofer N, Skawran S, Heimer J, et al. Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res. 2024;14(1):36. https:\/\/doi.org\/10.1186\/s13550-024-01097-3.","journal-title":"EJNMMI Res"},{"issue":"5","key":"2298_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02298-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02298-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02298-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:16:36Z","timestamp":1791008196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02298-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":27,"alternative-id":["2298"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02298-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board and the local ethics committee of the Medical Faculty of the University of Cologne (25-1272-retro, approval date: 03.04.2026) and was conducted according to the Declaration of Helsinki and the Good Clinical Practice guidelines. The databases used in the study are the intellectual property of the University Clinic of Cologne. The need for informed consent was waived by the Ethics Committee due to the retrospective nature of the study. Data was protected by the pseudoanonymization process.","order":1,"name":"Ethics","label":"Ethical Approval & Consent to participate & to publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.D. discloses research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, SOFIE, Eisai and Novartis\/AAA; Speaker Honorary and\/or Advisory Boards fees from Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis\/AAA and Bayer Vital; Stock from Siemens Healthineers, Lantheus Holding; a patent pending for 18 F-PSMA-JK-7 (PSMA imaging tracer). DU reports research funding by the Collaborative Research Center 1451 (Sonderforschungsbereich 1451) unrelated to this project. Other authors state no conflict of interest. No funds, grants, or other support were received during the preparation of this manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}